With a market capitalization (market cap) of $1.33B — a measure of how much the company is worth — MannKind Corporation ranks #2,232 among the 2,416 companies tracked, and 311th in Healthcare as of November 17, 2026. Shares trade at $4.13, up 4.17% on the day.
As of November 17, 2026 · Prices may be delayed
of 2,416 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series and can differ when the share count changes. Returns below show the total change over each period. Use the CAGR calculator to calculate an annualized return. CAGR calculator. Market cap vs. stock price.
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation November 13, 2026. The headline market cap is from the ranking update on November 17, 2026.
| Year | As of | Market cap | Annual change | Share-price close |
|---|---|---|---|---|
| 2026Latest available | Nov 13, 2026 | $1.32B | -24.35% | $4.13 |
| 2025 | Dec 31, 2025 | $1.75B | -10.43% | $5.67 |
| 2024 | Dec 31, 2024 | $1.95B | +98.81% | $6.43 |
| 2023 | Dec 29, 2023 | $981.52M | -29.29% | $3.64 |
Ranking figure $1.33B as of November 17, 2026.
Market cap = share price × shares outstanding.
MannKind Corporation's ranking market cap is the reported market cap from the latest ranking update, with a share price of $4.04 as of November 17, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $1.32B on November 13, 2026. See how the ranking works.
Current shares outstanding are unavailable from the latest quote. Shares outstanding vs. float.
The latest annual report (FY 2025) used a weighted-average 305,639,000 shares. That figure is an average for the year, not the live count in the market-cap formula.
Multiplying the latest price by those FY 2025 weighted-average shares would give about $1.23B. The ranking uses the provider's reported market cap instead, which reflects a current share count rather than that annual average.
Book equity: assets minus liabilities on the latest annual report.
FY 2025
FY 2025
Latest price ÷ annual earnings per share
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Quote as of . Prices may be delayed. Day figures refer to the quote's trading session.
Latest quote: $4.04. The headline price of $4.13 is from the ranking update on Nov 17, 2026. These updates can differ in timing.
Largest U.S.-listed companies in the same sector. These companies may serve different markets.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #11 | Eli Lilly and Company LLY | $1.33T | -1.18% |
| #20 | Johnson & Johnson JNJ | $673.59B | -0.98% |
| #23 |
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2025.
Visit websiteAs of November 17, 2026, MannKind Corporation (MNKD) is worth $1.33B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2025, MannKind Corporation’s book equity is about −$51.02M. Market cap is the market value of the outstanding shares. As of November 17, 2026, its market cap is $1.33B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
MannKind Corporation ranks #2,232 among the 2,416 companies tracked on MarketCapLens. In Healthcare it ranks #311 of 350.
Financial figures are annual and labeled with their fiscal year (FY). Current-price P/E uses the latest available share price and annual earnings per share.
| 2022 | Dec 30, 2022 | $1.39B | +26.10% | $5.27 |
|---|
| 2021 | Dec 31, 2021 | $1.1B | — | $4.37 |
|---|
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
FY 2025
Return on equity data unavailable for FY 2025
FY 2025
Return on assets data unavailable for FY 2025
FY 2025
| $517.75B |
| -0.60% |
| #30 | UnitedHealth Group Incorporated UNH | $354.98B | -3.92% |
| #31 | Merck & Co., Inc. MRK | $354.79B | -0.39% |
| #37 | Novartis AG NVS | $301.28B | -0.42% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #2229 | Cimpress plc CMPR | $1.33B | -2.44% |
| #2230 | American Assets Trust, Inc. AAT | $1.33B | -0.73% |
| #2231 | First Mid Bancshares, Inc. FMBH | $1.33B | -1.31% |
| #2233 | Arlo Technologies, Inc. ARLO | $1.33B | +0.24% |
| #2234 | HBT Financial, Inc. HBT | $1.32B | -1.29% |
| #2235 | TriMas Corporation TRS | $1.32B | +1.11% |
MannKind Corporation’s ranking market cap of $1.33B comes from the same snapshot as the rest of this site, as of November 17, 2026. It is not share price multiplied by the FY 2025 weighted-average share count of 305,639,000. The historical market-cap series last observed $1.32B on November 13, 2026.
Over the past year, MannKind Corporation’s market cap is down 14.66%, using historical market-cap records rather than today’s share count applied to past prices.
MannKind Corporation (MNKD) shares trade at $4.13, up 4.17% on the day, as of November 17, 2026.
MannKind Corporation trades at a live price-to-earnings (P/E) ratio of 201.8, using the latest share price divided by the latest annual earnings per share. That is not the same as a fiscal-year reported P/E.